Earnings Call Summary | RCM Technologies(RCMT.US) Q2 2024 Earnings Conference
Earnings Call Summary | RCM Technologies(RCMT.US) Q2 2024 Earnings Conference
Adjusted diluted EPS for Q2 2024 increased by 12.0%, from $0.50 to $0.56.The following is a summary of the RCM Technologies, Inc. (RCMT) Q2 2024 Earnings Call Transcript:
以下是RCm Technologies, Inc.（RCMT）2024年第二季度業績會簡報：
Financial Performance:
金融業績：
Consolidated gross profit for Q2 2024 increased by 6.6% year-over-year from $18.8 million to $20.0 million.
Adjusted EBITDA for Q2 2024 grew by 10.8%, from $6.5 million to $7.2 million.
Adjusted diluted EPS for Q2 2024 increased by 12.0%, from $0.50 to $0.56.
Engineering gross profit grew by 23.7%, while Life Sciences Data & Solutions gross profit decreased by 17.9%.
Healthcare Q2 gross profit grew by 8.6%.
2024年第二季度，營業收入總毛利潤同比增長6.6％，從1,880萬美元增至2,000萬美元。
2024年第二季度調整後的EBITDA從650萬美元增長10.8％，至720萬美元。
2024年第二季度攤薄後每股收益同比增長12.0％，從0.50美元增至0.56美元。
工程總毛利潤增長23.7％，而生命科學數據和解決方案總毛利潤下降了17.9％。
醫療保健第二季度的總毛利潤增長了8.6％。
Business Progress:
業務進展：
Significant expansion in Engineering, especially with Energy Services' revenue and EBITDA exceeding forecasts and expanding in Lat Am and Europe.
The Healthcare division successfully added many new school districts, improving recruitment and credentialing processes.
Life Sciences continues to demonstrate growth through solutions integrated approach, including a quality control project in Puerto Rico for a major pharma packaging company.
Aerospace and Defense experienced mixed results but maintains healthy EBITDA and a continued focus on customer requirements.
工程部門顯着擴張，特別是能源服務的營收和EBITDA超過預期，在拉美和歐洲繼續擴張。
醫療保健部門成功地新增了許多新的學區，改善了招聘和認證流程。
生命科學部門通過解決方案綜合方法持續呈現增長，包括針對一家主要製藥包裝公司在波多黎各的質量控制項目。
航空航天和國防經歷了不同程度的結果，但保持健康的EBITDA，並繼續專注於客戶需求。
Opportunities:
機會：
Continued strong contribution from Engineering along with the increased strength in other divisions expected in the back half of the year.
工程部門持續強勁貢獻其它部門在後半年的增長預計將繼續增強。
Risks:
風險：
Life Science commercial practice leads the growth but exhibits variability and dependence on high-margin projects.
生命科學商業實踐引導增長，但對高利潤項目存在變異性和依賴性。
More details: RCM Technologies IR
更多細節請參閱RCm Technologies IR。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
